Literature DB >> 3413081

Unusual lipid structures selectively reduce the toxicity of amphotericin B.

A S Janoff1, L T Boni, M C Popescu, S R Minchey, P R Cullis, T D Madden, T Taraschi, S M Gruner, E Shyamsunder, M W Tate.   

Abstract

Ribbon-like structures result when amphotericin B interacts with lipid in an aqueous environment. At high ratios of amphotericin to lipid these structures, which are lipid-stabilized amphotericin aggregates, become prevalent resulting in a dramatic attenuation of amphotericin-mediated mammalian cell, but not fungal cell, toxicity. Studies utilizing freeze-etch electron microscopy, differential scanning calorimetry, 31P NMR, x-ray diffraction, and optical spectroscopy revealed that this toxicity attenuation is related to the macromolecular structure of the complexes in a definable fashion. It is likely that amphotericin in this specific form will have a much improved therapeutic utility.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3413081      PMCID: PMC281917          DOI: 10.1073/pnas.85.16.6122

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  14 in total

1.  Novel multilayered lipid vesicles: comparison of physical characteristics of multilamellar liposomes and stable plurilamellar vesicles.

Authors:  S M Gruner; R P Lenk; A S Janoff; M J Ostro
Journal:  Biochemistry       Date:  1985-06-04       Impact factor: 3.162

Review 2.  31P nuclear magnetic resonance and the head group structure of phospholipids in membranes.

Authors:  J Seelig
Journal:  Biochim Biophys Acta       Date:  1978-07-31

3.  Polyene antibiotic-sterol interactions in membranes of Acholeplasma laidlawii cells and lecithin liposomes. I. Specificity of the membrane permeability changes induced by the polyene antibiotics.

Authors:  B de Kruijff; W J Gerritsen; A Oerlemans; R A Demel; L L van Deenen
Journal:  Biochim Biophys Acta       Date:  1974-02-26

4.  Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B.

Authors:  G Lopez-Berestein; R Mehta; R L Hopfer; K Mills; L Kasi; K Mehta; V Fainstein; M Luna; E M Hersh; R Juliano
Journal:  J Infect Dis       Date:  1983-05       Impact factor: 5.226

5.  Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes.

Authors:  R R New; M L Chance; S Heath
Journal:  J Antimicrob Chemother       Date:  1981-11       Impact factor: 5.790

6.  Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study.

Authors:  G Lopez-Berestein; V Fainstein; R Hopfer; K Mehta; M P Sullivan; M Keating; M G Rosenblum; R Mehta; M Luna; E M Hersh
Journal:  J Infect Dis       Date:  1985-04       Impact factor: 5.226

7.  Differences in the interaction of the polyene antibiotic amphotericin B with cholesterol- or ergosterol-containing phospholipid vesicles. A circular dichroism and permeability study.

Authors:  A Vertut-Croquin; J Bolard; M Chabbert; C Gary-Bobo
Journal:  Biochemistry       Date:  1983-06-07       Impact factor: 3.162

8.  Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells.

Authors:  R Mehta; G Lopez-Berestein; R Hopfer; K Mills; R L Juliano
Journal:  Biochim Biophys Acta       Date:  1984-03-14

9.  Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.

Authors:  G Lopez-Berestein; G P Bodey; L S Frankel; K Mehta
Journal:  J Clin Oncol       Date:  1987-02       Impact factor: 44.544

10.  Treatment of murine cryptococcosis with liposome-associated amphotericin B.

Authors:  J R Graybill; P C Craven; R L Taylor; D M Williams; W E Magee
Journal:  J Infect Dis       Date:  1982-05       Impact factor: 5.226

View more
  45 in total

1.  Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B.

Authors:  Maryam Iman; Zhaohua Huang; Francis C Szoka; Mahmoud R Jaafari
Journal:  Int J Pharm       Date:  2011-01-26       Impact factor: 5.875

2.  Lipid complexing decreases amphotericin B inflammatory activation of human neutrophils compared with that of a desoxycholate-suspended preparation of amphotericin B (Fungizone).

Authors:  G W Sullivan; H T Carper; G L Mandell
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

3.  A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections.

Authors:  A Adedoyin; C E Swenson; L E Bolcsak; A Hellmann; D Radowska; G Horwith; A S Janoff; R A Branch
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

4.  Amphotericin B induces interdigitation of apolipoprotein stabilized nanodisk bilayers.

Authors:  Thanh-Son Nguyen; Paul M M Weers; Vincent Raussens; Zhen Wang; Gang Ren; Todd Sulchek; Paul D Hoeprich; Robert O Ryan
Journal:  Biochim Biophys Acta       Date:  2007-10-16

5.  In vitro and in vivo antifungal activities of liposomal amphotericin B, and amphotericin B lipid complex.

Authors:  K Mitsutake; S Kohno; Y Miyazaki; T Noda; H Miyazaki; T Miyazaki; M Kaku; H Koga; K Hara
Journal:  Mycopathologia       Date:  1994-10       Impact factor: 2.574

Review 6.  Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential.

Authors:  G Gregoriadis; A T Florence
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

7.  Immunological effects of amphotericin B and liposomal amphotericin B on splenocytes from immune-normal and immune-compromised mice.

Authors:  J J Schindler; R P Warren; S D Allen; M K Jackson
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

8.  Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B.

Authors:  K M Wasan; M G Rosenblum; L Cheung; G Lopez-Berestein
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

9.  In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid.

Authors:  V Joly; R Farinotti; L Saint-Julien; M Chéron; C Carbon; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

10.  Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidiasis.

Authors:  K M Wasan; J S Conklin
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.